Price
242.45
+1.99%52W Range
Market Cap
₹573.55 Cr
Traded: ₹0.56 Cr (0.10%) 0.0x
Free Float: ₹66.76 Cr (0.84% of FF traded)
Volume · 60D trend
23.66 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -15.0% | -13.0% | -- | -3.0% | Accelerating |
| ROE | -- | -45.0% | -64.0% | -- | -- | Decelerating |
| Return | +20.0% | +5.0% | +12.0% | +139.0% | -- | Accelerating |
| Profit | -- | +14.0% | +24.0% | -- | +89.0% | Accelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Sep 2019PDF ↗ | Jun 2019PDF ↗ | Sep 2018PDF ↗ | Jun 2018PDF ↗ | |
|---|---|---|---|---|
| Sales | 12 | 7 | 9 | 12 |
| Expenses | 12 | 10 | 9 | 14 |
| Operating Profit | -0 | -3 | 0 | -2 |
| OPM % | -3.3% | -41.8% | 2.0% | -15.2% |
| Other Income | 1 | 0 | -0 | 0 |
| Interest | 0 | 0 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 |
| Profit Before Tax | -1 | -4 | -1 | -4 |
| Tax % | 7.3% | -42.6% | 4.1% | -1.1% |
| Net Profit | -1 | -2 | -1 | -4 |
| Exceptional Items | -- | -- | -- | -- |
| EPS (Rs) | -2.5 | -0.9 | -0.5 | -1.5 |
| Sales Growth (YoY) | 30.9% | -42.7% | -- | -- |
| Sales Growth (QoQ) | 68.9% | -22.5% | -26.0% | -- |
| OP Growth (YoY) | -311.1% | -57.1% | -- | -- |
| OP Growth (QoQ) | 86.7% | -- | 109.9% | -- |
| Profit Growth (YoY) | 54.0% | 39.0% | -- | -- |
| EPS Growth (YoY) | -361.1% | 39.6% | -- | -- |
| EPS Growth (QoQ) | -176.7% | -66.7% | 63.8% | -- |
| OP Margin | -3.3% | -41.8% | 2.0% | -15.2% |
| Net Margin | -5.1% | -31.1% | -14.5% | -29.5% |
| Material Cost % | 77.0% | 93.0% | 64.0% | 92.0% |
| Employee Cost % | 21.0% | 34.0% | 25.0% | 16.0% |
| P/S | 14.63 | -- | -- | -- |
| P/E | -- | -- | -- | -- |
| P/B | 11.25 | -- | -- | -- |
Exchange Filings
50We herewith enclose the Newspaper Publication for the 31st Annual General Meeting of the Company published in ''Business Standard'' and ''Makkal Kural'' on August 20, 2026.
We herewith enclose the Notice of 31st Annual General Meeting of the Company scheduled to be held on Friday, September 11, 2026 at 10.00 A.M along with the Annual Report of the Company ....
We herewith enclose the Annual Report of the Company for the F.Y 2025-2026.
Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026.
We herewith enclose the intimation for Book Closure and Cut-Off dates for the purpose of 31st Annual General Meeting of the Company.
We hereby inform that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 11, 2026 at 10.00 A.M through Video Conferencing (VC) / Other Audio ....
We herewith enclose the Unaudited Financial Results for the Quarter ended June 30, 2026 as approved by the Board of Directors in its meeting held on August 11, 2026.
We hereby inform you that the Board of Directors in their meeting held on August 11, 2026 inter-alia considered and approved i) Unaudited Financial Results of the Company for the Quarter ....
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026.
Intimation for Closure of Trading Window
Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.
Intimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026.
Newspaper Publication for the Audited Financial Results of the Company for the Quarter & Year ended March 31, 2026 as published in "Financial Express" and "Makkal Kural" on May 31, 2026.
We herewith enclose the Audited Financial Results of the Company along with the Statutory Auditor''s Report for the Quarter and Year ended March 31, 2026, as approved by the Board of Directors ....
We hereby inform you that the Board of Directors in their meeting held on May 29, 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditor's ....
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....
We hereby submit our response to the Clarification sought by the Stock Exchange regarding the movement in the Share Price of the Company.
Certificate under Regulation 74(5) of SEBi (DP) Regulations, 2018 for the Quarter ended March 31, 2026.
The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on April 13, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
The Board of Directors of the Company in the Meeting held on March 27, 2026 has inter-alia considered and approved: (i) The appointment of M/s. K. S. Rao & Co., Chartered Accountants, Chennai ....
Intimation for Closure of Trading Window.
We hereby submit our response to the clarification sought by the Stock Exchange regarding the movement in the share price of the Company.
The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on March 23, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Nine-Months ended December 31, 2025 as published in "Business Standard" and "Makkal Kural" on ....
The Board of Directors of the Company in their Meeting held on February 11, 2026 has inter-alia considered and approved the Un-Audited Financial Results of the Company along with the Limited ....
The Board of Directors of the Company in the Meeting held on February 11, 2026 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
We hereby inform you that the Outlook of the Credit Ratings assigned to the Bank loan facilites of the Company has been revised by ICRA Limited.
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended December 31, 2025.
Intimation for Closure of Trading Window.
We hereby enclose the Newspaper publication of the extract of the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2025, as published in "Business ....
The Board of Directors of the Compant in the meeting held on November 11, 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....
The Board of Directors of the Company in the Meeting held on November 11, 2025 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited ....
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 ,inter alia, to consider and approve the Un-Audited Financial ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended September 30, 2025.
Intimation for Closure of Trading Window
We hereby inform that the Members at the 30th Annual General Meeting of the Company held on September 19, 2025 had inter-alia approved (i) Appointment of Mr. Navin Kumar as Independent ....
We hereby inform that the Members at the 30th Annual General Meeting of the Company held on September 19, 2025 had inter-alia approved (i) Appointment of Mr. Navin Kumar as Independent ....
We herewith enclose the Outcome / Proceedings of the 30th Annual General Meeting of the Company held on September 19, 2025.
We herewith enclose the Newspaper Publication in connection with 30th Annual General Meeting of the Company.
We herewith enclose the Notice of 30th Annual General Meeting of the Company scheduled to be held on Friday, September 19, 2025 at 10.00 A.M, for the FY 2024-2025.
We herewith enclose the Annual Report of the Company for the F.Y 2024-2025.
Intimation for Book Closure for the purpose of 30th Annual General Meeting of the Company.
We hereby inform that the 30th Annual General Meeting of the Company (AGM) is scheduled to be held on Friday, September 19, 2025 at 10.00 A.M through Video Conferencing (VC) / Other Audio ....
We hereby enclose the Newspaper Publication of the Extract of the Unaudited Financial Results of the Company for the Quarter ende June 30, 2025 in "Business Standard" and "Makkal Kural" ....
We hereby inform that the Board of Directors at its Meeting held on 12/08/2025 has approved the re-appointment of Mrs. Ravichandran Chitra (DIN: 07749125) and Mr. Palamadai Krishnan Sundaresan ....
We hereby inform that the Board of Directors at its meeting held on 12/08/2025 has approved the Re-appointment of Mrs. Ravichandran Chitra (DIN: 07749125) and Mrs. Palamadai Krishnan Sundaresan ....
Unaudited Financial Results for the Quarter Ended June 30, 2025.
The Board of Directors in the meeting held on 12/08/2025 has inter-alia approved i) Unaudited Financial Results of the Company for the Quarter ended June 30, 2025 along with the Limited ....
Annual Reports
14